{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-114809","form_type":"8-K","ticker":null,"cik":"0001173281","company_name":"NeuBase Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.412758+00:00","generated_at":"2026-06-08T19:08:57.400811+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"NeuBase receives Nasdaq deficiency notice; bid price below $1.00 for 30 days","bullets":["Nasdaq notified NeuBase on Nov 3, 2023 that its common stock bid price has been below $1.00 for 30 consecutive business days.","Company has 180 days, until May 1, 2024, to regain compliance by closing at $1.00 or higher for at least 10 consecutive business days.","If not cured by May 1, NeuBase may qualify for a second 180-day period by meeting other listing standards and providing a reverse split plan.","The notice does not immediately affect trading on Nasdaq; stock continues to trade under symbol NBSE.","Company intends to monitor bid price and consider options to regain compliance, but no assurance of success."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-114809","json":"https://secwatch.observer/filing/0001104659-23-114809.json","markdown":"https://secwatch.observer/filing/0001104659-23-114809.md","text":"https://secwatch.observer/filing/0001104659-23-114809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1173281/000110465923114809/0001104659-23-114809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1173281/000110465923114809/tm2330001d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T19:08:57.400811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf1bd015c430bb9bc89c3696c476b07ecdcd1280","claim":"NeuBase Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"ule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”),","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1173281/000110465923114809/0001104659-23-114809-index.htm","confidence":0.95,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}